May 11, 2022 6:30am EDT FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
May 02, 2022 8:30am EDT FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Apr 28, 2022 8:30am EDT Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th
Apr 25, 2022 8:30am EDT Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases
Apr 11, 2022 6:30am EDT Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Mar 04, 2022 8:30am EST Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference
Mar 01, 2022 8:30am EST Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022
Feb 17, 2022 8:30am EST Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Feb 14, 2022 8:30am EST Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Feb 09, 2022 6:30am EST Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
